269 related articles for article (PubMed ID: 34292496)
1. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
Jiang Y; Sarpong EM; Sears P; Obi EN
Infect Dis Ther; 2022 Feb; 11(1):111-126. PubMed ID: 34292496
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Watt M; McCrea C; Johal S; Posnett J; Nazir J
Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
[TBL] [Abstract][Full Text] [Related]
3. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
Whitney L; Nesnas J; Planche T
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Budget Impact Analysis of Fidaxomicin Treatment for Clostridioides difficile Infections (CDI) in Germany.
Siefen AC; Kurte MS; Bauer AM; Cornely OA; Wingen-Heimann S; Kron F
Expert Rev Pharmacoecon Outcomes Res; 2024 May; ():. PubMed ID: 38712561
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
11. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.
Diaz-Pollan B; Carrasco Molina S; Marcelo C; de Gea Grela A; Martínez-Martín P; Jiménez-González M; Moreno Ramos F; Mora-Rillo M
Cureus; 2023 Nov; 15(11):e48735. PubMed ID: 38094526
[TBL] [Abstract][Full Text] [Related]
13. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
[TBL] [Abstract][Full Text] [Related]
14. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
15. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
Cornely OA; Watt M; McCrea C; Goldenberg SD; De Nigris E
J Antimicrob Chemother; 2018 Sep; 73(9):2529-2539. PubMed ID: 29800295
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of
Hernando-Gozalo M; Rescalvo-Casas C; Seijas-Pereda L; Cuadros-González J; Pérez-Tanoira R
Heliyon; 2024 May; 10(10):e30742. PubMed ID: 38803946
[TBL] [Abstract][Full Text] [Related]
17. The Risk of
Hall RG; Cole TJ; Shaw C; Alvarez CA
Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326759
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
[TBL] [Abstract][Full Text] [Related]
19. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
Stabholz Y; Paul M
Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
Burton HE; Mitchell SA; Watt M
Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
